NOVEL has led 300+ Projects, Won 15+ Awards and Nominations
Recognized Leader for Drug & Device Strategy
NOVEL Health Strategies is an award winning team of experienced professionals with expertise in healthcare strategy, research, policy, publications, health economics and outcomes research, modeling, and pricing and market access. NOVEL's team has led strategy projects for majority of top 50 pharmaceutical, biotech and device companies. NOVEL has large network of internal and external stakeholders and has published several thought leading strategy perspectives.
Our Team in News
During 2011-2020 NOVEL's team was interviewed and quoted by The New York Times, Scientific American, Fast Company and Nature Medicine.
Our team has published over 300 studies in healthcare. These studies have been cited by hundreds of publications.
NOVEL Health Strategies Selected for 15 Peer-Reviewed Presentations including PODIUM Presentation at ISPOR 2020
Indirect Treatment Comparison (ITC) by NOVEL Health Strategies for a Breakthrough Therapy for Movement Disorder
AWARD Winning Study on Market Access Trends by NOVEL
NOVEL's team recently conducted a comprehensive study on market access trends of Top 100 selling drugs. This study won PLATINUM medal by AMCP and was also nominated by ISPOR as award finalist.
Annual Strategy Perspective in Nature Biotechnology
Our annual strategy series has been cited and quoted more than two hundred times. This series was published in Nature Biotechnology (Journal Impact Factor 30+).
Please Email or Call us. We will greatly appreciate an opportunity to introduce ourselves to you. If NOVEL can help world's number one selling brand and other major products, we are sure we could add immense value to your product's HEOR, Clinical or Medical Strategy